“That was a little bit intimidating,” recalls West, now the vice president and general manager of Illumina's DNA sequencing business unit following the acquisition of Solexa Ltd. by Illumina.

Deep-pocketed investors have adopted a bullish approach towards Illumina ILMN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of California lost 18% and 15%, respectively. We recently published a list of Jim ...

In June 2007, Stanford's David Johnson teamed up with Barbara Wold of Pasadena's California Institute of Technology, using Illumina's Solexa platform to develop a high-throughput method for ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...